Olive AI: The Perils of Unvalidated Healthcare AI

The quiet shuttering of a high-profile AI company like Olive AI tells you more about deploying tech in a hospital than any hyped-up success story ever could. For health system CIOs looking at automation, this isn’t just one company going under. It’s a perfect case study of what happens when advanced tech hits a clinical environment without a real foundation of evidence. That case, filed away with the documented flameouts of Theranos and Babylon Health, gives us a critical review set showing the same pattern over and over: clinical AI failure isn’t some sudden, catastrophic crash. It’s a quiet, unexamined deployment where the sales pitch far outruns any third-party validation.

The Unexamined Deployment: What the Shutdown Record Shows

The Olive AI shutdown is an important entry in the health tech logbook for anyone trying to understand the risk of deploying something without evidence. This has nothing to do with their balance sheet or who was running the company. It’s about the total lack of a strategy for generating continuous proof that the tool was working, a strategy that absolutely must come before and during any AI integration into patient care. When you inject automation without that critical layer, its actual effect on clinical outcomes, on how you use your resources, or on patient safety is just a theory. This is exactly where Harlan Krumholz’s outcomes research gives us the right lens, because he’s always asking what a deployment actually changed for the patient Harlan Krumholz research on healthcare outcomes. In the rush to grab what looks like a new efficiency, that basic question goes unanswered. The real problem these shutdowns expose is the canyon between a great capability story and a verifiable clinical benefit you can point to. A traditional medical device has its efficacy and safety locked down through trials before it ever gets near a patient, but AI solutions (especially machine learning ones) are designed to evolve. Without a defined plan for managing that evolution, a health system is basically deploying a moving target. The recorded histories of Theranos, which promised a revolution in diagnostics without any peer-reviewed proof, and Babylon Health, which went bankrupt in August 2023 and had its UK business sold for parts, are just different chapters of the same story. They all represent a version of that same gap between huge claims and the third-party evidence that has to be there for clinical adoption.

The Missing Evidence Layer in AI Deployment

The evidence layer that was missing in these cases is about a sustained, ongoing commitment to proving impact and managing change. For an AI tool, particularly Software as a Medical Device (SaMD), this layer has a few parts. First, you need rigorous prospective studies, not just looking back at old data, to prove the tool is useful and safe in a real-world clinic. Lots of AI tools are first validated on the company’s own internal data, which rarely reflects the messy reality of your patient population or the workflows in your hospital. Second, this missing layer must include constant monitoring for algorithmic drift. Any model trained on yesterday’s data will eventually get tripped up by today’s data, causing its performance to degrade, and without a plan to catch this drift, its effectiveness can quietly evaporate, putting patients at risk. So, as a CIO, are you asking the vendor how their solution is built to detect and adapt when your patient demographics shift, or when new treatment protocols are introduced? Is there a clear, transparent, and clinically governed plan for retraining, revalidating, and redeploying the model? If there isn’t, you’re turning a potentially helpful tool into an unmonitored liability. Finally, the evidence layer demands that the vendor tells you exactly what the AI is supposed to do and what its limits are. Vague promises about “intelligent” capabilities without defining precisely what the AI can and can’t do (and under what specific conditions) just opens the door for misuse and clinical mistakes.

The FDA PCCP Framework: A Contrast in Change Control

The unexamined deployment model stands in sharp contrast to the FDA’s Predetermined Change Control Plan (PCCP) framework, which is a solid answer for managing how AI/ML-driven SaMD evolves. The FDA put out the final guidance for its PCCP on September 15, 2026. A PCCP is basically a pre-approved roadmap that lets a manufacturer make defined changes to their AI/ML device over time without needing a whole new premarket submission for every single update FDA guidance on Predetermined Change Control Plans. This isn’t just another regulatory hoop to jump through. It’s a real safeguard built to make sure that the constant learning and adapting of an AI doesn’t break its safety or effectiveness. With a PCCP, the manufacturer has to spell out the exact kinds of changes they plan to make, the methods they’ll use to make them, and the performance metrics they’ll use to check their work on the modified device. This gets into the weeds of their data management, their model update procedures, and their validation protocols. For a health system CIO, knowing if a vendor’s AI operates under a PCCP (or something just as strong) is a top priority. It pushes the job of continuous validation off your plate and back onto the vendor, who is now accountable to a regulator for keeping the device safe and performing as advertised for its entire life. The PCCP framework tackles the problem of unexamined deployment head-on by forcing an evidence and change-management strategy right from the start. It makes sure the AI’s “capability story” can’t just run wild between regulatory check-ins, because it’s tied to a pre-approved, transparent, and clinically validated plan for its own evolution.

The Deployment Question to Ask First

For any health system CIO, the lesson from the Olive AI shutdown and the pattern we see with Theranos and Babylon Health is this: the first question to ask before deploying any AI isn’t “what can it do?” It’s “what’s the proof it changes anything, and how will you keep that proof current as the AI evolves?” This moves the conversation away from aspirational marketing and toward verifiable impact and solid governance. When you’re vetting an AI solution, you have to demand a complete plan for performance monitoring, drift detection, and a clear change-control process. Is the vendor operating under an FDA PCCP, or can they show you an equally transparent and clinically governed process for managing their model updates? Do they have a serious Quality Management System (QMS) in place, like ISO 13485, especially since the FDA’s Quality Management System Regulation (QMSR) now incorporates ISO 13485:2016 by reference, effective February 2, 2026? ISO 13485 standard for medical devices. The pattern across these recorded failures reveals a basic truth. Clinical AI failure is rarely a loud bang. It’s the slow, quiet result of an unexamined deployment, where the lack of a continuous evidence layer lets risks grow in the dark. A defined change-control plan, based on regulatory discipline and clinical outcomes research, is the recorded answer and the necessary defense against the appeal of unproven automation. Making that evidence layer a priority will be the sign of responsible AI adoption in healthcare.